<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356276</url>
  </required_header>
  <id_info>
    <org_study_id>HIPEC-01</org_study_id>
    <nct_id>NCT02356276</nct_id>
  </id_info>
  <brief_title>Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2</brief_title>
  <acronym>EHTLAGCRGD2</acronym>
  <official_title>A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIPEC-01 is a prospective, open, randomized multicenter phase III clinical study conducted in
      China. To determine the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the
      treatment of locally advanced gastric cancer, patients are randomized into HIPEC group and
      control group. In HIPEC group, the patients undergo radical gastrectomy with D2
      lymphadenectomy and HIPEC with paclitaxel and postoperative chemotherapy. Patients in the
      control group just undergo radical gastrectomy with D2 lymphadenectomy followed by
      postoperative chemotherapy. Patients in both groups receive 6-8 cycles of postoperative
      systemic chemotherapy (XELOX or SOX regimens) and are followed up for 5 years or until death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer (GC) is the fourth most common cancer, and the second leading cause of
      cancer-related death worldwide. Advances in diagnostic and therapeutic approaches have
      achieved long-term survival for early GC. However, receiving perioperative/postoperative
      systemic chemotherapy and gastrectomy with D1-D2 lymph node dissection, 5-year survival rates
      of advanced gastric cancer remain under 30%. 40-60% of recurrences are peritoneal and/or
      locoregional. hyperthermic intraperitoneal chemotherapy (HIPEC) technique is increasingly
      used in the curative treatment of primary and digestive peritoneal carcinomatosis, in
      association with cytoreductive surgery. Theoretically, HIPEC eliminates free cancer cells
      that can be released into peritoneal cavity during the gastrectomy and prevents peritoneal
      carcinomatosis recurrences. The benefit of using HIPEC as an adjuvant treatment for advanced
      gastric cancer has been reported in several randomized studies and a meta-analysis. Surgical
      resection combined with HIPEC significantly reduces the peritoneal recurrences and improves
      the overall survival of GC patients. But there is not a prospective and randomized phase III
      clinical study of HIPEC in the treatment of locally advanced gastric cancer after radical
      surgery in China so far.

      In order to evaluate the survival benefit and safety of radical surgery and HIPEC followed by
      postoperative chemotherapy in local advanced gastric cancer, patients who fulfill the
      inclusion and exclusion criteria will be recruited in this study and randomized to two
      treatment groups (HIPEC group and control group). In HIPEC group, the patients undergo
      radical gastrectomy with D2 lymphadenectomy and HIPEC with paclitaxel and postoperative
      chemotherapy. Patients in the control group just undergo radical gastrectomy with D2
      lymphadenectomy followed by postoperative chemotherapy. Patients in both groups receive 6-8
      cycles of postoperative systemic chemotherapy (XELOX or SOX regimens) . Patients are followed
      up for 5 years and the survival outcome will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2015</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>assess overall survival during 5 years in both study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>assess progression-free survival rate during 5 years in both study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver metastatic rate</measure>
    <time_frame>5 years</time_frame>
    <description>calculate the percent of liver metastatic in both two arms during 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>calculate the percent of local recurrence in both two arms during 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>5 years</time_frame>
    <description>determine percent of adverse events or side effects according to NCI criteria, Common Terminology Criteria for AE (CTCAE 4.0).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CEA mRNA expression of peritoneal lavage fluid</measure>
    <time_frame>Through study completion, an average of 3 year</time_frame>
    <description>Quantitative RT-PCR is used to analyze CEA mRNA expression of peritoneal lavage fluid before and after D2 lymphadenectomy between two arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">584</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>HIPEC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by 6-8 cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.
Systemic chemotherapy (XELOX or SOX regimens):
XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.
If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 6-8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-8 cycles of systemic chemotherapy (XELOX or SOX regimens) were performed after radical gastrectomy with D2 lymphadenectomy.
XELOX regimen is Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.
If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid (S-1: BSA &lt;1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA&gt;1.5m^2, 60 mg bid), po, day 1-14, every 3 weeks for a total of 6-8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 lymphadenectomy</intervention_name>
    <arm_group_label>HIPEC group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>surgical resection or radical surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy</intervention_name>
    <description>The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.</description>
    <arm_group_label>HIPEC group</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic chemotherapy (XELOX or SOX regimens)</intervention_name>
    <description>XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.
SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40 mg/m^2 bid, po, day 1-14 (S-1: BSA &lt;1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA&gt;1.5m^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles.</description>
    <arm_group_label>HIPEC group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>XELOX or SOX regimens</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 &lt; age ≤ 70 years old

          -  Male or Non pregnant female

          -  The Eastern Cooperative Oncology Group (ECOG) status 0-1

          -  T3 or T4 gastric adenocarcinoma (visual determination according to AJCC 2010 7th
             edition)

          -  No distance metastasis, eligible for D2 lymphadenectomy

          -  Have not received cytotoxic chemotherapy, radiotherapy or immunotherapy

          -  White blood cells &gt; 4,000/mm3

          -  neutrophils ≥ 1,500/mm3

          -  platelets ≥ 100,000/mm3

          -  hemoglobin&gt;9g/l

          -  Alanine transaminase (ALT) and aspartate aminotransferase (AST) &lt; or = 2.5 times upper
             limit of nominal (ULN)

          -  total bilirubin (TBIL) &lt; 1.5 times ULN

          -  serum creatinine &lt; 1 times ULN

          -  Having given written informed consent prior to any procedure related to the study

        Exclusion Criteria:

          -  Have other cancer within 5 years

          -  Existence of distance metastasis during surgey (M1)

          -  Prior malignant tumors with detectable signs of recurrence or distant metastasis

          -  Poorly controlled disease e.g. atrial fibrillation, stenocardia, cardiac
             insufficiency, persistent hypertension despite medicinal treatment, ejection
             fraction&lt;50%

          -  Epileptic seizures patients need medicine control

          -  Uncontroled mental disease or mental disorder

          -  Drug abuse or psychological or social factors affect the judgment of results

          -  Contraindication to any therapy contained in this regimen specific to the study

          -  Receiving other chemotherapy, radiotherapy or immunotherapy

          -  Without given written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shuzhong cui, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Tumor Hospital of Guangzhou Medical University Recruiting</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shuzhong cui, M.D</last_name>
    <phone>0086-138-0251-3800</phone>
    <email>cuishuzhong@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xian-Zi Yang, M.M</last_name>
    <phone>0086-188-9853-4167</phone>
    <email>7097359@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Peng, M.D</last_name>
      <phone>0086-137-0132-3669</phone>
      <email>pengzheng301@sina.com</email>
    </contact>
    <investigator>
      <last_name>Zheng Peng, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Wei Zhou, M.D</last_name>
      <phone>0086-139-0222-2859</phone>
      <email>zhouzhw@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiao-Xi Zhu, M.B</last_name>
      <phone>0086-138-0881-5489</phone>
      <email>zhuxx@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhi-Wei Zhou, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Li, M.D</last_name>
      <phone>0086-138-2217-7479</phone>
      <email>yuan821007@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Ze-Jian Lv, M.M</last_name>
      <phone>0086-137-9819-1490</phone>
      <email>648593454@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yong Li, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shuzhong cui, M.D</last_name>
      <phone>0086-138-0251-3800</phone>
      <email>cuishuzhong@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhen Tang, M.M</last_name>
      <phone>0086-159-2081-9128</phone>
      <email>57932181@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>shuzhong cui, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Wang, M.D</last_name>
      <phone>0086-136-0283-8202</phone>
      <email>gdphtcmwanjin@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wen-Jun Xiong, M.M</last_name>
      <phone>0086-159-2055-3177</phone>
      <email>xiongwj1988@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jin Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo-Xin Li, M.D</last_name>
      <phone>0086-138-0277-1450</phone>
      <email>gzliguoxin@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Hao Liu, M.D</last_name>
      <phone>0086-138-2215-8578</phone>
      <email>liuhaofbi@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guo-Xin Li, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bao-Jun Zhou, M.M</last_name>
      <phone>0086-136-0311-7586</phone>
      <email>zhoubaojun67@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shao-Wei Ma, M.M</last_name>
      <phone>0086-137-3331-4055</phone>
      <email>13733314055@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bao-Jun Zhou, M.M</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Medical University Fourth Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Li, M.D</last_name>
      <phone>0086-311-8609-5678</phone>
      <email>li_yong_hbth@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qing-Wei Liu, M.M</last_name>
      <phone>0086-159-3105-9506</phone>
      <email>liuqingwei_10@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yong Li, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuan Wang, M.D</last_name>
      <phone>0086-139-3624-3918</phone>
      <email>88008008@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Guan-Yu Zhu, M.D</last_name>
      <phone>0086-187-4612-6777</phone>
      <email>zhuguanyu001@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kuan Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guang-Sen Han</last_name>
      <phone>0086-138-0381-8006</phone>
      <email>hnhanguangsen@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Yang, M.M</last_name>
      <phone>0086-151-3893-9753</phone>
      <email>294859420@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guang-Sen Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital, China</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai-Xiong Tao, M.D</last_name>
      <phone>0086-135-0715-5452</phone>
      <email>tao_kaixiong@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ke Wu, M.D</last_name>
      <phone>0086-135-4524-8289</phone>
      <email>wuke201288@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kai-Xiong Tao, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong-Liang Yao, M.D</last_name>
      <phone>0086-138-0845-2603</phone>
      <email>Yaohl0326@163.com</email>
    </contact>
    <contact_backup>
      <last_name>San-Lin Lei, M.D</last_name>
      <phone>0086-139-7499-1477</phone>
      <email>13974991477@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hong-Liang Yao, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Liang, M.M</last_name>
      <phone>0086-130-1138-3125</phone>
      <email>tjlianghan@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xue-Jun Wang, M.D</last_name>
      <phone>0086-</phone>
      <email>wxjsimon@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Han Liang, M.M</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin-Bao Wang, M.D</last_name>
      <phone>0086-139-0652-3036</phone>
      <email>wangxb@zjcc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chao Hu, M.D</last_name>
      <phone>0086-137-3589-3334</phone>
      <email>huchao1987pj@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xin-Bao Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2015</study_first_posted>
  <last_update_submitted>October 29, 2017</last_update_submitted>
  <last_update_submitted_qc>October 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced gastric cancer</keyword>
  <keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
  <keyword>radical gastrectomy with D2 lymphadenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

